A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH ...

THR-beta agonists are the only medication approved to treat metabolic dysfunction–associated steatohepatitis (MASH), a severe ...

Promising Nonalcoholic Steatohepatitis Therapies such as AZD2693, Saroglitazar Magnesium 4 mg, Semaglutide (SEMA), Cilofexor ...

The presentation featured lipidomic data on improvements in polyunsaturated fatty acid triglycerides and LDL cholesterol ... disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease ...

Clearance of Investigational New Drug (IND) application for FASN Inhibitor TVB-3567, to be developed for the treatment of acne SAN MATEO, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Sagimet Biosciences ...

Ton Annual Supply of VK2735 Active Pharmaceutical Ingredient. Secures Dedicated Fill/Finish Capacity for 100 Million Annua ...

One-third of children with metabolic dysfunction-associated steatotic liver disease receiving standard of care showed improvement after 2 years.

Chia seeds can stabilise blood sugar by slowing down the absorption of carbohydrates, making them beneficial for people with diabetes or those at risk of developing it ...

(NALD)(Shutterstock) According to him, NAFLD, if severe and progressing, can lead to an irreversible condition—liver cirrhosis, with non-alcoholic steatohepatitis (NASH) and liver fibrosis as ...

In its early stages, simple fatty liver (steatosis) is relatively harmless and reversible. However, if liver fat continues to accumulate, it can lead to non-alcoholic steatohepatitis (NASH), a ...

About 25% of NAFLD patients progress to a more severe stage including liver inflammation (nonalcoholic steatohepatitis, NASH) and scarring (liver fibrosis), which can lead to cirrhosis or even ...

According to the updated Lancet Commission study, untreated vision loss and high levels of low-density lipoprotein (LDL), commonly known as "bad" cholesterol, could increase the risk of developing ...